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Abstract
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and
characterized by progressive somatic disfigurement (mainly involving the face and extremities) and
systemic manifestations. The prevalence is estimated at 1:140,000–250,000. It is most often
diagnosed in middle-aged adults (average age 40 years, men and women equally affected). Due to
insidious onset and slow progression, acromegaly is often diagnosed four to more than ten years
after its onset. The main clinical features are broadened extremities (hands and feet), widened
thickened and stubby fingers, and thickened soft tissue. The facial aspect is characteristic and
includes a widened and thickened nose, prominent cheekbones, forehead bulges, thick lips and
marked facial lines. The forehead and overlying skin is thickened, sometimes leading to frontal
bossing. There is a tendency towards mandibular overgrowth with prognathism, maxillary
widening, tooth separation and jaw malocclusion. The disease also has rheumatologic,
cardiovascular, respiratory and metabolic consequences which determine its prognosis. In the
majority of cases, acromegaly is related to a pituitary adenoma, either purely GH-secreting (60%)
or mixed. In very rare cases, acromegaly is due to ectopic secretion of growth-hormone-releasing
hormone (GHRH) responsible for pituitary hyperplasia. The clinical diagnosis is confirmed
biochemically by an increased serum GH concentration following an oral glucose tolerance test
(OGTT) and by detection of increased levels of insulin-like growth factor-I (IGF-I). Assessment of
tumor volume and extension is based on imaging studies. Echocardiography and sleep apnea testing
are used to determine the clinical impact of acromegaly. Treatment is aimed at correcting (or
preventing) tumor compression by excising the disease-causing lesion, and at reducing GH and IGF-
I levels to normal values. Transsphenoidal surgery is often the first-line treatment. When surgery
fails to correct GH/IGF-I hypersecretion, medical treatment with somatostatin analogs and/or
radiotherapy can be used. The GH antagonist (pegvisomant) is used in patients that are resistant
to somatostatin analogs. Adequate hormonal disease control is achieved in most cases, allowing a
life expectancy similar to that of the general population. However, even if patients are cured or
well-controlled, sequelae (joint pain, deformities and altered quality of life) often remain.
Disease name and synonyms
Acromegaly (derived from the Greek words "akros",
extremities, and "megas", big). This term was proposed by
Pierre Marie, a famous French neurologist working in La
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description of the disease and its pathology in 1886. It is
used when the disease begins in adulthood.
Gigantism: when the disease begins during childhood.
Prosopectasia (derived from the Greek words "prosopon",
face, and "ektasis", stretching): used by Verga, an Italian
anatomist, in 1864.
Definition
Acromegaly is characterized by an acquired progressive
somatic disfigurement, mainly involving the face and
extremities, but also many other organs, that is associated
with systemic manifestations. The disease is related to the
excessive production of growth hormone (GH). This GH
hypersecretion originates from a monoclonal benign pitu-
itary tumor (adenoma) in more than 90% of cases.
Epidemiology
Acromegaly is a rare disease, with a prevalence of 40 to 70
cases per million inhabitants and an annual incidence of
3 to 4 new cases per million inhabitants [1]. However, a
recent study performed in Belgium suggests that pituitary
adenomas may be more prevalent than previously
thought, and thus the prevalence of acromegaly would be
around 100–130 cases per million inhabitants [2]. A very
recent epidemiological study (conducted in Germany [3]
where screening of acromegaly was performed by means
of systematic insulin-like growth factor-I (IGF-I) measure-
ment in primary care patients of the general population
on a given day) found a prevalence of biochemical
acromegaly even higher (1,043 per million). Such high
figures need to be confirmed. Owing to its insidious
onset, acromegaly is often diagnosed late (4 to more than
10 years after onset), at an average age of about 40 years.
The disease affects both men and women equally [4-6].
Clinical description [6-9]
The dysmorphic syndrome [6,10]
The extremities (hands and feet) are broadened, the fin-
gers are widened, thickened and stubby, and the soft tis-
sue is thickened (Figure 1). The patient may have had to
enlarge his or her ring in recent years, or to change shoe
size. The facial aspect is characteristic, and patients with
established acromegaly are generally alike in this respect:
the nose is widened and thickened, the cheekbones are
obvious, the forehead bulges, the lips are thick and the
facial lines are marked (Figure 2). The forehead and over-
lying skin is thickened, sometimes leading to frontal boss-
ing. There is a tendency towards mandibular overgrowth
with prognathism, maxillary widening, teeth separation
and jaw malocclusion. Photographs show a slow, insidi-
ous transformation over several years. The diagnosis is
often raised by a doctor who has never seen the patient
before. The deformations can also affect the rest of the
skeleton and, in severe chronic forms, dorsal kyphosis
with deformation of rib cage may be observed, leading to
the classical "punchinello" aspect, especially when GH
hypersecretion begins prior to closure of the epiphyses.
Symptoms
Acromegaly can cause a variety of symptoms, such as mal-
odorous sweating (especially at night); headache
(whether the pituitary adenoma is large or small);
acroparesthesia (carpal tunnel syndrome); and joint pain.
A progressive deepening of the voice is also observed.
Facial aspect of a patient with acromegalyigure 2
Facial aspect of a patient with acromegaly. The nose is 
widened and thickened, the cheekbones are obvious, the 
forehead bulges, the lips are thick and the facial lines are 
marked. The forehead and overlying skin is thickened, some-
times leading to frontal bossing.
As compared with the hand of a normal person (left), the hand of a patient with acromeg ly ( ight) is enlarg d, the fin-gers are widened, thickene and stubby, and the so  tissue is thickenedFigure 1
As compared with the hand of a normal person (left), the 
hand of a patient with acromegaly (right) is enlarged, the fin-
gers are widened, thickened and stubby, and the soft tissue is 
thickened.Page 2 of 17
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:17 http://www.ojrd.com/content/3/1/17Skin changes
Nearly 70% of patients have sweaty, oily skin. Skin thick-
ening is due to glycosaminoglycan deposition and to
increased collagen production by connective tissue. Skin
tags are frequent and may be a marker of colonic polyps.
Raynaud's disease is present in one-third of cases.
Bone changes
Craniofacial
In response to both GH and IGF-I, periosteal new bone
formation leads to an increase in skeletal growth, espe-
cially at the level of the mandible (prognathism); jaw
thickening, teeth separation, frontal bossing, malocclu-
sion, and nasal bone hypertrophy are the usual facial
bony deformities seen in acromegaly (Figure 3).
Radiography shows a thickening of the cranial vault and
protuberances, frontal internal hyperostosis, condensa-
tion of the walls of the sella turcica with clinoid hypertro-
phy. Hypertrophy of the sinuses, especially the frontal
sinuses, is also clearly visible. This, along with laryngeal
hypertrophy, explains why the voice in acromegaly tends
to become deeper and has a sonorous resonance.
Extremities
These changes are not only due to soft tissue hypertrophy
and excess growth of bone and cartilage but also to bone
deformation. Indeed, radiography is abnormal in half of
the cases, showing distal tufting of the phalanges, widen-
ing of the base of phalanges with osteophyte formation,
enthesopathy (mineralization of ligamentous insertion),
widening of diaphysis in cortical bone, and widening of
joint spaces due to cartilage hypertrophy [11].
Trunk
Bony deformation also affects the spine, with upper dor-
sal kyphosis and compensatory lumbar hyperlordosis.
Vertebral enlargement, widened intervertebral spaces and
osteophyte formation also being observed. The thorax is
deformed due to protuberance of the lower portion of the
sternum, and by elongation and divergence of the ribs
(due to overgrowth of the chondrocostal joints) (Figure
4).
In longstanding forms, bony deformation affects the spine, with upper dorsal kyphosis and compensatory lumbar hyper-lordosiFigure 4
In longstanding forms, bony deformation affects the 
spine, with upper dorsal kyphosis and compensatory 
lumbar hyperlordosis. The thorax is deformed due to 
protuberance of the lower portion of the sternum, and by 
elongation and divergence of the ribs.
Mandibular overgrowth leads to prognathism, maxillary wid-eni g, teeth separation and jaw mal cclusionFigure 3
Mandibular overgrowth leads to prognathism, maxillary wid-
ening, teeth separation and jaw malocclusion.Page 3 of 17
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Imaging studies show diaphyseal cortical thickening of
the long bones and widened joint spaces, sometimes with
osteophytes.
Bone mineral density
Bone remodeling is stimulated in acromegaly. Cortical
bone thickens (as measured by the metacarpal index and
histomorphometric parameters) and its porosity is dimin-
ished. The trabecular bone mass may be decreased, nor-
mal or increased. Measurement of spinal bone mass can
give contradictory results, probably because acromegaly is
often associated with other endocrine disorders that inter-
fere with bone mass. In general, bone mass is normal in
the lumbar spine in patients with isolated acromegaly, but
is decreased in patients with associated hypogonadism
[12], as it is generally the case for hypogonadism whatever




Peripheral joint symptoms are very frequent [13,14].
Arthralgia and myalgia occur in 30%–70% of patients. All
the joints can be affected (typically the large joints: knees,
shoulders, hands, wrists and hips). Acromegalic arthropa-
thy develops within an average of ten years after diagnosis.
The arthralgia is mainly mechanical, degenerative, non-
inflammatory in origin but features of osteoarthritis may
develop in some patients. Joint mobility (especially of the
shoulders) can be limited in the later stages of the disease.
Joint effusion is rare and synovial aspirate shows a gener-
ally degenerative picture without evidence of inflamma-
tion, but may also point to the presence of calcium
microcrystals (associated chrondrocalcinosis).
Physical examination of joints often provides little infor-
mation. The abnormalities are generally minor as com-
pared to the subjective functional discomfort. The
shoulders and hips may show a loss of mobility and func-
tion. In contrast, some patients have joint hyperlaxity.
There is no correlation between the presence (or severity)
of arthropathy and the age of onset of acromegaly, or the
mean GH or IGF-I concentration at baseline or during fol-
low-up. Arthropathy appears to be more frequent after age
of 45 years.
Radiological studies show a widening of the joint spaces,
reflecting hypertrophy of the hyaline cartilage, the pres-
ence of osteophytes, bone proliferation at the attachment
sites of tendons and ligaments, periarticular calcium
deposit and exostosis of the bone surface. The joint space
subsequently diminishes due to destructive arthropathy.
Sonography shows a thickening of the cartilage in the
shoulder, wrist and knee joints, which improves during
treatment for acromegaly [15].
The arthropathy progresses inexorably in advanced stages
and unpredictably in minor forms. It is not influenced by
successful treatment of acromegaly, with the exception of
diffuse articular symptoms and some sites of pain.
Spinal involvement
The estimated prevalence of spinal involvement is about
40% to 50%. Backache is more frequent at the level of the
lumbar spine than cervical or dorsal spine. The pain is
mainly mechanical in nature, but inflammatory features
can occur (16%). Spinal involvement may be accompa-
nied by nerve compression. Occasionally, bilateral inter-
mittent claudication reveals lumbar spinal stenosis
Radiological examination shows typical features: ossifica-
tion of the anterior and lateral surface of the vertebral
bodies contributing to enlarging their anteroposterior
diameter; a biconcave vertebral appearance and scallop-
ing of the vertebral bodies (exaggerated concavity of the
posterior vertebral wall). The mechanism is poorly under-
stood, and may involve hypertrophy of the intraspinal
soft tissues (ligamentous hypertrophy, epidural lipomato-
sis) or of the bone. In more severe cases, the process of
ossification of the anterior surface of the vertebral bodies
can bridge the disc space and give the aspect of diffuse idi-
opathic skeletal hyperostosis.
Neuropathies
Symptomatic carpal tunnel syndrome is frequent (occurs
in 20%–50%, up to 75% of patients at diagnosis). Nerve
conduction studies have documented that the vast major-
ity of acromegalic patients have subclinical abnormalities
of nerve conduction. Magnetic resonace imaging (MRI)
shows an increase in the amplitude and intensity of the
median nerve signal in the patients with symptomatic car-
pal tunnel syndrome compared to asymptomatic patients
[16]. The mechanism appears to involve median nerve
edema more than extrinsic compression due to an excess
of connective tissue, bony or synovial hypertrophy, or an
increase in extracellular fluid within the carpal tunnel
itself with Schwann cell demyelination. The nerve edema
improves when GH and IGF-I levels fall, suggesting that
hormonal control is a key prerequisite for improving neu-




Hypertension occurs in 20% to 50% of patients. Its prev-
alence increases with time after the onset of acromegaly,
the GH level, and age. It is at least partly due to chronic
hypervolemia (the plasma volume is 10% to 40% abovePage 4 of 17
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distal tubule level) [17,18]. Hypertension can also result
from endothelial dysfunction [19]. Neither renin angi-
otensin aldosterone nor sympathetic systems seem to be
involved in the pathogenesis of hypertension. Insulin
resistance and diabetes may also play a role in the onset of
hypertension [20,21]. Sleep apnea syndrome is likely to
contribute also to the pathogenesis of hypertension.
Specific cardiomyopathy
Cardiac involvement is a consistent feature of acromegaly.
Many lines of evidence, especially from experimental
studies, point to the existence of specific cardiac disorders
in acromegaly, independently of coronary involvement
(found in a minority of patients nowadays) and valve dis-
orders [8,22,23].
Initially, the cardiac involvement is asymptomatic (at
least at rest), and consists mainly of myocardial hypertro-
phy (of the interventricular septum and left ventricular
posterior wall), as assessed by echocardiography, but the
dimensions of the left ventricle are normal (concentric
hypertrophy). It can occur in the absence of hypertension,
and even in young patients (< 30 years), reflecting the role
of GH itself on the myocardium. Hypertension further
aggravates cardiac hypertrophy. Echocardiography and
isotope studies show altered diastolic function (abnormal
left and right ventricle filling) related to abnormal relaxa-
tion (parietal stiffness is, at least in part, probably linked
to edematous infiltration of the ventricular wall and per-
haps also to a certain degree of fibrosis). Clinical symp-
toms such as dyspnea during exercise may be observed
while the patient is asymptomatic at rest. Systolic function
is normal at this stage (again, at least at rest), thanks to
increased myocardial contractility. A hyperkinetic syn-
drome (increased cardiac index) is always present. Systolic
function is altered during exercise, however. Even at this
early stage, arrhythmias and/or conduction disorders may
occur. Their prevalence in acromegaly was underesti-
mated for many years. In fact, ventricular premature com-
plexes occur in about 40% of patients with acromegaly,
and, in one study, systematic 24 h Holter electrocardio-
gram (ECG) recordings showed complex ventricular
arrhythmias in 48% of patients (compared to only 12% of
controls). Most of these arrhythmias are subclinical and
persist despite successful treatment of acromegaly. Myo-
cardial remodeling, hypertrophy and fibrosis all are likely
to play a role in their onset.
Congestive heart failure can occur if the cardiac disorders
progress (if GH hypersecretion persists and, probably, if
other risk factors such as diabetes, hypertension, and sleep
apnea are also present); functional signs appear on effort
at first, before becoming permanent. At this stage,
echocardiography shows variable degrees of cavity dila-
tion. Fortunately, these severe forms are now far less fre-
quent (prevalence 3%) [24].
A number of cardiovascular parameters improve during
effective treatment of acromegaly, even if some lesions
may appear to be irreversible in certain patients. In gen-
eral, younger patients and patients with a relatively short
history of acromegaly show better "recovery" (from
diastolic disorders, myocardial hypertrophy or systolic
dysfunction). In contrast, when dilated congestive heart
failure occurs, cardiac function (especially systolic func-
tion) may show a short-term improvement, allowing
some patients to survive or to avoid heart transplantation,
but the longer-term prognosis is worse than that of
patients with heart failure due to other causes (5-year
mortality rate 37%).
Valve disease
The increased prevalence of valve disorders can also con-
tribute to the onset or aggravation of the heart disease in
patients with acromegaly [25]. The risk of valve disease
increases with time from onset [26], and these abnormal-
ities often persist after effective treatment of acromegaly.
They may be related to fibrotic changes.
Metabolic complications
Physiologically, GH increases blood glucose levels, exerts
a lipolytic effect, and promotes triglyceride hydrolysis into
free fatty acids and glycerol.
GH excess leads to insulin resistance at the level of the
liver or in the periphery that leads to hyperinsulinemia.
The prevalence of diabetes in acromegalic patients ranges
from 20% to 56%, and that of glucose intolerance ranges
from 16% to 46%, depending on the series [8]. As long as
the compensatory increase in insulin secretion by pancre-
atic β cells counterbalances the reduction in insulin sensi-
tivity, glucose tolerance remains normal. Impaired
glucose tolerance occurs when insulin secretion is altered,
and is followed by diabetes. There is a link between glu-
cose tolerance, hypertension and acromegalic cardiomy-
opathy [20].
Acromegaly is associated with decrease in fat mass and
increase in lean body mass [27].
Respiratory complications
Sleep apnea affects 60%–80% of all patients with acrome-
galy (more often men) and 93% of patients with signs of
this disorder. Sleep apnea is more likely to be sought in
patients who snore (reported by 78% of patients with
acromegaly) and those with daytime sleepiness (51%), or
morning fatigue and morning headache (16%). Sleep
apnea may be a contributory factor in hypertension and
cardiovascular disease. In most cases the apnea is obstruc-Page 5 of 17
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Obstructive apnea is linked to anatomical changes due to
mandibular and maxillary growth, soft-tissue thickening
(especially of the palate and uvula) and changes in the
angles of the different bone segments, leading to hyper-
collapsibility of the posterior and lateral hypopharyngeal
walls. Hypertrophy of the tongue also plays a role [28], as
does hypertrophy of the submaxillary glands.
Changes in respiratory function are frequent but less well
documented. Anatomical modifications of thoracic bones
and cartilage (leading to profound changes in the geome-
try of the rib cage) and mechanical changes in thoracic
elasticity and inspiratory muscles can lead to ventilatory
disorders. Respiratory muscle strength is also abnormal.
The inspiratory time is shorter and the breathing fre-
quency may increase.
Patients with acromegaly often have an increase in their
total lung capacity (81% of men and 56% of women),
owing to an increase in alveolar volume. An obstruction is
found in 20% to 30% of patients (small airway or upper
airway narrowing). Subclinical hypoxemia may be
present. No ventilation-perfusion mismatching has been
demonstrated.
The apnea-hypopnea index improves during effective
treatment of acromegaly, along with the obstructive apnea
index and oximetry values [28,29]. However, while apnea
can disappear in some patients whose acromegaly is
cured, other require nocturnal positive end expiratory
pressure for persistent sleep apnea.
Neoplasia and acromegaly
Gastrointestinal tumors
The issue of colon cancer risk in acromegaly is controver-
sial [30]. The relative risk of colon cancer, compared with
the general population, has been widely overestimated at
10 to 20, whereas it is, in reality, probably only 2 to 3
[31,32]. As colon cancer may be the consequence of colon
polyps degeneration, many studies have been done to
assess the prevalence of colon polyps in patients with
acromegaly. Prospective studies show that up to 45% of
patients with acromegaly have colonic polyps, which are
adenomatous in 24% of cases [33] and can arise from all
sites of colon. There is no clear correlation between GH
and IGF-I concentrations and the incidence of colonic
polyps. Recommendations concerning colonoscopy in
acromegaly are a matter of controversy. It seems reasona-
ble to propose that, unless intestinal symptoms occur ear-
lier, colonoscopy has only to be done first at age 50 years,
whatever the progressive status and duration of acromeg-
aly, or the history of colonic disease. As always, colonos-
copy must be preceeded by careful bowel preparation and
be done by a skilled operator, because it is often difficult
in this setting (patients with acromegaly have a longer
colon). When an adenomatous colonic polyp is discov-
ered, an interval of three years before repeating the exam-
ination seems reasonable.
Thyroid nodules
Goiter is found in 25% to 90% of patients with acromeg-
aly. The risk of developing thyroid nodules increases with
the time since the onset of acromegaly. Multinodular
goiter is autonomous in 10% to 20% of patients, some-
times causing patent thyrotoxicosis. Thyroid nodules are
generally harmless, and the risk of thyroid cancer does not
seem to be higher than in the general population.
Other cancers (lung, breast, prostate, etc.) are not over-rep-
resented in patients with acromegaly [30].
Etiology [34,35]
Acromegaly of pituitary origin
More than 95% of patients with acromegaly have a benign
monoclonal pituitary adenoma which develops from the
somatotrope cells that normally produce GH in the pitui-
tary. Thus, these adenomas are termed somatotrope ade-
noma.
a) Somatotrope pituitary adenomas
Somatotrope pituitary adenomas may be pure or mixed.
Pure somatotrope pituitary adenomas (60%) contain
either cells rich in secretory granules that show diffuse
immunostaining (such densely granulated somatotrope
adenoma are observed in older patients with slow disease
progression) or cells poor in secretory granules with scat-
tered immunolabelling (sparsely granulated somatotrope
adenomas are seen in younger patients with a more rap-
idly progressing disease) [34]. Some of these pure soma-
totrope adenomas also express free alpha-subunit, which
is common to the glycoprotein hormones follicle-stimu-
lating hormone (FSH), luteinizing hormone (LH), thy-
roid-stimulating hormone (TSH) and chorionic
gonadotropin hormone (CG, co-localized in the same
cells or even in the same granules as GH) [36].
Some adenomas are mixed. Mixed GH- and prolactin
(PRL)-secreting adenomas are frequent (25%). Some ade-
nomas contain both cell types, while other develop from
a mammosomatotropic stem cell and consist of more
mature monomorphic cells that express both GH and PRL
[34]. Rare adenomas can also co-secrete an excess of TSH,
in which case the clinical picture combines acromegaly
and hyperthyroidism with inappropriate secretion of TSH
[37,38]. Very rarely, corticotrophin (ACTH) hypersecre-
tion may also be found.Page 6 of 17
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In the large majority of cases adenomas are benign. Excep-
tional pituitary carcinomas (less than 20 cases published)
may be observed and the presence of distant metastases is
generally required to support the diagnosis of malignancy
[39].
c) Silent somatotrope adenomas
Some somatotrope adenomas are not associated with sys-
temic GH hypersecretion or GH hypersecretion is very
mild. In such cases, clinical acromegaly is not observed,
but GH immunolabeling of the excised tumor (generally
resected because of local tumor symptoms) is positive
[40]. However, when analyzed very carefully at hormonal
level, it may be possible to discover subtle abnormalities
in GH/IGF-I hypersecretion in these cases [41].
d) Pathogenesis of somatotrope adenomas
The pituitary/hypothalamic origin of these adenomas is
controversial [42]. Some lines of evidence point to a
hypothalamic origin. In this case, the main actor would be
growth-hormone-releasing hormone (GHRH), which can
cause not only hyperplasia of somatotrope cells but also,
as demonstrated in some animal models, actual adeno-
mas. In contrast, the monoclonal nature of the tumors
and the absence of relapse after total tumor resection
points instead to a pituitary origin [6]. In fact, the initia-
tion and/or progression of malignant transformation of
normal somatotropes could be due to a polyclonal hyper-
plastic response of these cells secondary to hypothalamic
dysregulation. The prerequisite for an abnormal response
to pathological GHRH secretion may be the existence of a
mutation in the somatotrope cell. Most human soma-
totrope adenomas seem to be associated with clonal
expansion [43] of cells bearing a somatic mutation. How-
ever, as for the other types of pituitary adenomas, isola-
tion of a single causative factor in sporadic pituitary
tumorigenesis has proved difficult. A mutated Gsα pro-
tein has been identified in up to 40% of somatotrope ade-
nomas. Mutations at two critical sites (gsp mutations)
inhibit GTPase activity and lead to constitutive adenyl-
cyclase activation [44]. In the pituitary, loss of heterozy-
gosity on chromosomes 11, 13 and 9 (particularly in inva-
sive macroadenomas), and an activating gene (PTTG,
pituitary tumor transforming gene), also play a role. This
latter gene (a securin homolog) is over-expressed in func-
tional pituitary tumors, which could lead to aneuploidy
[45]; the degree of over-expression correlates with tumor
size and invasiveness.
Finally, even if it is clear that somatotropes cells are
altered in somatotrope adenomas, the sequence of events
leading to their clonal expansion seems to be multifacto-
rial. An activated oncogene may be necessary to initiate
tumorigenesis, while promotion of cell growth may
require GHRH or other growth factors, such as bFGF
(basic fibroblast growth factor) [46,47].
e) Genetic syndromes with acromegaly
McCune-Albright syndrome, which is associated with
multiple fibrous bone dysplasia, precocious puberty and
café-au-lait spots, can be accompanied by acromegaly.
This syndrome is related to a somatic mutation that acti-
vates the alpha subunit of Gs protein [48].
Acromegaly can also be associated with hyperparathy-
roidism, neuroendocrine tumors (e.g. gastrinoma, insuli-
noma or a non-functional pancreatic tumor), adrenal and
other endocrine and non-endocrine tumors in patients
with multiple endocrine neoplasia type 1 (MEN1), which
is related to a germline mutation of the menin gene in
many cases [49,50].
When acromegaly is associated with bilateral pigmented
micronodular adrenal hyperplasia (causing ACTH-inde-
pendent hypercorticism) and with cutaneous lesions or
cardiac myxomas, the patient should be screened for the
Carney complex, which is often related to a germline
mutation of the regulatory 1-α subunit of protein kinase
A (PRKAR1A) [51,52].
Very recently, familial acromegaly related to germline
mutations of the AIP (aryl hydrocarbon receptor interact-
ing protein) gene have been described [53]. These muta-
tions may also, albeit rarely, be responsible for sporadic
cases of acromegaly, in particular in young patients [54-
56].
Extrapituitary acromegaly
GH hypersecretion does not always have a pituitary ori-
gin. Acromegaly can be due to eutopic hypothalamic
GHRH hypersecretion (gangliocytoma, hamartoma, chor-
istoma, glioma, etc.) or, more often, to ectopic, peripheral
GHRH hypersecretion (pancreatic or bronchial carcinoid
tumor) that stimulate the normal somatotropes to
become hyperplastic and to hypersecrete GH. The diagno-
sis is based on plasma GHRH assay (revealing excess secre-
tion) and on identification of the GHRH-secreting
endocrine tumor [57].
GH can also be hypersecreted by an ectopic pituitary ade-
noma (sphenoidal sinus, petrous temporal bone,
nasopharyngeal cavity) or, in exceptional cases, by a
peripheral tumor (pancreatic islet tumor or lymphoma)
[58,59].
Diagnosis of acromegaly
The diagnosis of acromegaly is clinical and needs to be
confirmed biochemically. Clinical diagnosis is suggested
by the typical disfigurement of the patient related to pro-Page 7 of 17
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appearance, as assessed by serial photographs. Diagnosis
is made biochemically by the findings of increased serum
GH concentrations that are not suppressed following an
oral glucose load (oral glucose tolerance test, OGTT). An
increase (with reference to the age-adjusted normal range)
in the serum concentration of IGF-I), the main GH-
dependent growth factor, confirms the diagnosis.
GH assays
The first GH assays, which began to be used 35 years ago,
were polyclonal competitive radio-immunoassays (RIAs);
their sensitivity was poor. Thereafter, over the last 25
years, non-competitive two-site antibody radioimmuno-
metric assays (IRMAs) have been introduced allowing for
enhanced sensitivity. Fifteen years ago, non-isotopic two-
site antibody assays began to become available, with the
major practical advantage being that some were auto-
mated [60]. This last type of assays is the most frequently
used today, at least in Europe. The differences in analytical
methodologies (RIA, IRMA, immunochemiluminescent
assay -ICMA-, Enzyme-linked immunoabsorbent assay -
ELISA-) are one explanation for the variability in GH
results. GH circulates in plasma as a mixture of different
molecular forms: 22 kDa GH, 20 kDa GH, a GH-binding
protein (GH-BP) linked form, dimers and polymers [61].
Use of polyclonal or monoclonal antibodies specific for
the predominant 22 kDa or for several of these different
isoforms contributes to bias.
Many standard GH preparations were used previously to
calibrate GH. Manufacturers were recently advised to cali-
brate their GH assay kits with the international standard
(IS) 98/574, which was established with recombinant
GH. According to a recent European consensus statement
on the standardization of GH assays [62], "the availability
of the second International Standard (IS) for GH (WHO
IS 98/574), a recombinant material consisting of 22 kDa
GH of more than 95% purity, provides the opportunity
for adoption of a single calibrant for GH immunoassays.
IS 98/574's well-defined chemical and physical properties
allow it to meet European Union legislation calls for all
laboratory results to be traceable to a defined material (In
vitro Diagnostics Medical Devices Directive, 98/79/EC)."
As a first step to standardizing GH measurement", they
"recommend the reporting of GH concentrations in μg/l
of IS 98/574 (1 μg corresponding to 3 IU somatropin)".
Which GH cutoff use for the diagnosis?
The basal plasma GH level (in the morning for example,
or at randomly selected times) is elevated in acromegaly.
However, high GH concentrations can also be found in
healthy subjects, owing to the episodic nature of GH
secretion, that can fluctuate between undetectable levels
(most of the time) and peaks of up to 30 μg/l (90 mIU/l)
(Figure 5). According to a 2000 Consensus statement [63],
basal GH and IGF-I measurement must be done when
acromegaly is suspected. A GH concentration below 0.4
μg/l (1.2 mIU/l) plus a normal IGF-I level rules out
acromegaly. If the GH is above 0.4 μg/l (1.2 mIU/l) and/
or if the IGF-I is elevated (as compared with age-adjusted
normal range), an oral 75 g glucose load (oral glucose tol-
erance test -OGTT-) must be performed. If the lowest GH
value (nadir) during OGGT is below 1 μg/l (3 mIU/l),
acromegaly can be ruled out. If it remains above 1 μg/l (3
mIU/l), acromegaly is confirmed. As detailed below, with
the generalized use of very sensitive assays nowadays, it
has recently been considered that this cutoff should be
decreased to 0.3 μg/l (0.9 mIU/l). Paradoxically, the
OGTT can stimulate GH secretion in about 10% of
patients with acromegaly.
IGF-I measurement
The IGF-I level increases in parallel to the log of the GH
concentration. It must be determined using age-adjusted
norms (levels fall with age). Pregnancy, puberty and the
post-pubertal period are accompanied by high IGF-I con-
centrations. The concentration of IGFBP3, the main IGF
carrier protein, is usually increased in patients with
acromegaly, but this marker offers little further diagnostic
information.
Stimulation tests
Some patients (up to 50%) have an increase in their GH
concentration after thyrotropin-releasing hormone (TRH)
and/or gonadotropin-releasing hormone (GnRH) stimu-
lation. These tests have no diagnostic value, however, nor
does the response to GHRH.
Difficult and borderline clinical situations
A few patients with clear clinical signs of acromegaly and
a high IGF-I level have a GH nadir of <1 μg/l (3 mIU/l)
during OGTT [41]. Thus, some authors have suggested
that when chemiluminescence or fluorometric assays with
very low detection limits are used (0.10 to 0.30 μg/l, i.e.
0.3 to 0.9 mIU/l), the OGTT positivity cutoff should not
be 1 μg/l (3 mIU/l) but rather 0.30 μg/l (1 mIU/l) [64].
Forthcoming guidelines should ratify the choice of this
new 0.30 μg/l cutoff (1 mIU/l) when using very sensitive
GH assays.
Other difficult problems include a typical clinical picture
of acromegaly in a patient with normal IGF-I and GH con-
centrations. This situation probably corresponds to cases
in which acromegaly has resolved spontaneously, proba-
bly through necrosis of a pituitary adenoma.
In some conditions such as diabetes mellitus, chronic
renal failure, pregnancy or at the time of puberty, GH and/Page 8 of 17
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nosis nor for the assessment of treatment efficacy.
Differential diagnosis
Lastly, some patients have acromegaloid features with
normal GH and IGF-I levels (pseudoacromegaly); in some
cases, severe insulin resistance is the proposed mecha-
nism.
Tumor and functional pituitary assessment
Once the diagnosis has been established, and before initi-
ating treatment for acromegaly, patients must undergo a




Headache is very frequent, and is typically retroorbital or
frontal. It is linked to the adenoma and also to GH hyper-
secretion itself.
Visual disorders
When the adenoma grows upwards it can compress the
optic chiasm, leading to visual field disturbances, which
begin in the mid-periphery of the superior temporal sec-
tors, then progress to bitemporal hemianopsia (Figure 6).
Persistent compression can lead to blindness. The visual
field and acuity must therefore be routinely assessed.
Other manifestations of local tumor effects
In the case of a huge tumor with suprasellar extension into
the third ventricle obstructing the foramen of Munro,
hydrocephaly can occur. Infrasellar extension can lead to
sellar floor lysis and invasion of the sphenoid sinus, with
the risk of cerebrospinal fluid rhinorrhea. Lateral exten-
sion of the adenoma into the cavernous sinus, which is far
more frequent, can compress the III, IV, V, or VI cranial
nerves, or even the temporal lobe (with a risk of focal epi-
lepsy).
Imaging studies
Frontal and profile radiography of the sella turcica should
nowdays be abandoned. When formerly performed, they
showed an increase in the size of the sella, demineraliza-
tion of its walls, or local erosion; in patients with very
large tumors, the contour of the sella turcica can disappear
completely; asymmetrically growing tumors produce a
double countour (lateral view) or obliquity of the sellar
floor (frontal view).
MRI is tending to replace computed tomography for imag-
ing in this setting. It is currently the neuroradiological
examination of choice for all patients with pituitary ade-
nomas, and especially for acromegalic patients.
Microadenomas (< 10 mm diameter) appear as rounded,
well-circumscribed, homogeneous and discreetly hypoin-
tense abnormalities on T1-weighted images (compared
with the healthy pituitary or with the white matter of the
brain stem); sometimes the adenoma is iso-intense in T1-
weighted images and thus difficult to distinguish from
normal pituitary before contrast injection. It can be hypo-
, iso- or hyperintense on T2-weighted images. After gado-
linium injection, microadenomas appear hypointense rel-
ative to the rest of the brain parenchyma (Figure 7) and
especially to the rest of the pituitary, which shows homog-
Frequent blood sampling with serum GH measurement shows that in normal subjects (left panel) GH can fluctuate between undet c a e levels (most of the ti e) and peaks of up to 30 μg/l (90 mIU/l), owing to the episodic nature of GH secretion, whil  in pati nts with acromegaly (an exam le is given on right panel), GH hypersecretion is continuous and GH n ver returns to undetec able levelsigur  5
Frequent blood sampling with serum GH measurement shows that in normal subjects (left panel) GH can fluctuate between 
undetectable levels (most of the time) and peaks of up to 30 μg/l (90 mIU/l), owing to the episodic nature of GH secretion, 
while in patients with acromegaly (an example is given on right panel), GH hypersecretion is continuous and GH never returns 
to undetectable levels.Page 9 of 17
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or bulging of a hemi-pituitary, global bulging with lifting
of the sellar diaphragm, and lateral deviation of the pitui-
tary stalk (usually away from the lesion).
Macroadenomas (> 10 mm diameter) are generally iso-
intense as compared with the rest of the white matter of
brain parenchyma on unenhanced T1-weighted images.
Gadolinium contrast medium is intensely taken up by
these lesions, which appear hyperintense in comparison
with the rest of the white matter of brain parenchyma
(Figure 8).
MRI can be used to study possible suprasellar expansion,
upwards towards the suprasellar cisterna and the chiasma,
which may be compressed, pushed back, or laminated.
Extension downwards towards the sphenoid sinus and
laterally to the cavernous sinus should also be evaluated.
Invasion of the cavernous sinus is difficult to diagnose, as
the adenoma may appear to invade the cavernous sinus
when it simply abuts the lateral wall. The only indisputa-
ble sign of cavernous sinus invasion is when the internal
carotid artery appears completely surrounded by the ade-
noma.
The lack of clear signs of an adenoma on MRI, or an
appearance showing a bulging, hyperplastic pituitary (Fig-
ure 9), suggests that the acromegaly is secondary to
ectopic GHRH secretion [4].
Functional pituitary investigations
By developing in the sellar fossa, the adenoma compresses
the healthy pituitary (or the pituitary stalk) and can alter
physiological pituitary secretion. A gonadotrope defi-
Pituitary microadenomaFigure 7
Pituitary microadenoma.
Goldman perimeter showing normal visual fields (upper panel) and bitemporlal quadranopsia due to optic chiasm compression by a pituitary ad noma (lower panel)Figure 6
Goldman perimeter showing normal visual fields (upper panel) and bitemporlal quadranopsia due to optic chiasm compression 
by a pituitary adenoma (lower panel).Page 10 of 17
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testosterone levels in men, and menstrual disorders in
women (amenorrhea in some cases) together with a
decline in estradiol levels (without rise in gonadotrophin
levels). Thyrotrope deficiency is diagnosed by a decrease
in T4 levels, while the TSH level is in the normal range.
Corticotrope deficiency can be evaluated by measuring
morning plasma cortisol levels and/or testing with
metyrapone, corticotropin-releasing hormone (CRH) or
ACTH, according to each center habits.
Prolactin (PRL) hypersecretion is present in 30% of cases,
either functional (secondary to impairment of hypotha-
lamic production of dopamine or compression of the
pituitary stalk by the tumor that impairs dopamine trans-
port to the pituitary), or due to a mixed adenoma secret-
ing both PRL and GH. Free alpha-subunit is hypersecreted
in 20% to 40% of cases of acromegaly. Hypersecretion can




The clinical aims are to relieve symptoms, to reduce the
volume of the pituitary tumor, to avoid tumor relapse,
and to improve long-term morbidity and mortality.
Recent epidemiological studies helped to refine the defi-
nitions of "cure" and good disease control, which are now
far more precise: the GH concentration (the mean of sev-
eral samples, or the nadir in the OGTT) must return to less
Acromegaly due to ectopic secretion of GHRH by a pancreatic tumor, metastasized to the liver (left) responsible for a pituitary hyperplasia, visible on pituitary MRI (right) and stimul tion of nor al somatotroph cells, leading to GH hypersecretion and acro egalyFigu  9
Acromegaly due to ectopic secretion of GHRH by a pancreatic tumor, metastasized to the liver (left) responsible for a pituitary 
hyperplasia, visible on pituitary MRI (right) and stimulation of normal somatotroph cells, leading to GH hypersecretion and 
acromegaly.
Pituitary macroadenoma with suprasellar extension, compressing the optic chiasmFigure 8
Pituitary macroadenoma with suprasellar extension, compressing the optic chiasm.Page 11 of 17
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IGF-I level must return to normal [63]. A stepwise thera-
peutic strategy using surgery and/or radiotherapy and/or
medical treatment (Figure 10) allows to achieve these
goals.
Surgery is generally first-line treatment
Tumor excision, usually by the trans-sphenoidal route, is
the most rapid way of reducing GH and IGF-I concentra-
tions in patients with acromegaly. Nevertheless, these lev-
els normalize in only 40% to 70% of cases [66-69],
depending on the size of the tumor (microadenomas are
more amenable to cure), preoperative GH concentrations
(the success rate is higher when GH concentrations are
low, i.e. <10 μg/l or 30 mIU/l), and the surgeon's experi-
ence. Endoscopic techniques are now currently used in the
majority of expert centers [70,71].
Surgical outcome is carefully assessed at three months.
When surgery fails to achieve good disease control, or
when surgery is impossible or contraindicated, patients
are offered radiotherapy and/or pharmacological treat-
ments.
Radiotherapy
Radiotherapy in this setting is generally external and cen-
tered on the tumor; an average total dose of 50 Gy is deliv-
ered in about twenty five daily sessions. Highly focused
irradiation (radiosurgery, stereotactic radiotherapy,
"gamma-knife", etc.) is now available in some centers,
and causes less damage to neighboring tissues. Fractioned
irradiation yields GH concentrations below 2 μg/l (6
mIU/l) and normal IGF-I levels in 5% to 60% of patients,
depending on the series, after a median follow-up of
about 7 years [72-75]. In studies with longer follow-up,
fractionated radiotherapy normalizes the IGF-I level in
more than 70% of patients after 10 years. Here again, the
baseline GH concentration seems to be predictive of treat-
ment outcome.
Radiotherapy leads to variable degrees of anterior pitui-
tary insufficiency in 80% to 100% of patients after 10–15
years. Complications such as radionecrosis and optic neu-
ropathy are now very rare. In contrast, the risk of stroke
may be increased, sometimes many years after irradiation
[76].
The precise role of stereotactic irradiation in this setting
(e.g. with a gamma-knife) is becoming clearer [77,78], but
long-term studies with strict endpoints are needed to tell
whether this approach is as effective and safer than exist-
ing alternatives. Results of a French series of 82 patients
indicate that efficacy is similar to that of fractionated radi-
otherapy [79]: an average of 4 years after the procedure,
less than 20% of patients have normal IGF-I levels and
GH <2 μg/l (<6 mIU/l). In any event, this "radiosurgery"
is reserved for patients with small lesions located at least
5 mm from the optic chiasma.
Medical treatment
Dopamine agonists
Bromocriptine attenuates moderately the symptoms of
acromegaly and reduces GH concentrations, but it nor-
malizes IGF-I levels in only 10% of patients. Cabergoline
appears to be more effective [80,81].
Somatostatin analogs
• Mechanism of action. Somatostatin analogs suppress
GH secretion by binding to somatostatin receptors, of
which there are five subtypes (SST), on somatotrope ade-
noma cells. These drugs exert their antisecretory and anti-
tumoral effects by acting on SST 2 and 5.
• Available preparations. Octreotide (Sandostatin®) can
be injected subcutaneously (SC), generally by the patient
him/herself, at a dose of 100 to 200 μg two or three times
a day. This was the first such analog to be marketed, in the
1980s, and represented a real therapeutic advance [82].
Sustained-release lanreotide (Somatuline® LP 30 mg) was
the first slow-release preparation to be marketed. It was
injected intramuscularly every 10 to 14 days (the fre-
quency of injections depends on the impact on the GH
concentration). Lanreotide is now available for deep SC
injection every 28 days, at doses of 60, 90 and 120 mg
(Somatuline® Autogel® 60, 90 or 120 mg). Octreotide LAR
(Sandostatin® LAR 10–20 or 30 mg) is the sustained-
release version of octreotide, and is administered intra-
Site of action of the different therapeutic tools in acromegalyFigure 10
Site of action of the different therapeutic tools in acromegaly. 
Surgery, radiotherapy, somatostatin anlogues and dopamine 
agonists act at the level of the pituitary adenoma, while GH-
receptor antagonists act in periphery by blocking the GH 
receptor and thus impairing the effects of GH on the differ-
ent tissues.Page 12 of 17
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the median dose, and is then adjusted (decreased or
increased) according to the GH concentration. Alterna-
tively, it is possible to increase or decrease the frequency
of injections.
• These drugs achieve GH concentrations below 2 μg/l (5
mIU/l) in 60% to 70% of patients, and normalize IGF-1
levels in 50% to 80% of patients [83-90]. Besides their
antisecretory effect, somatostatin analogs also reduce the
tumor volume (generally the suprasellar portion) in 20%
to 70% of patients [88,91]. The reduction in tumor vol-
ume is larger when a somatostatin analog is the first-line
treatment [88].
• In selected cases (contra-indications to surgery, patients
with severe comorbidities who need to be prepared by
medical treatment before surgery [92], invasive tumors for
which total removal is unlikely [87,93]) somatostatin
analogs may be given as first-line therapy.
• Disadvantages: These treatments must be continued
indefinitely because Somatostatin analog only suppress
GH hypersecretion. They have gastrointestinal adverse
effects, which are generally transient, and cause gallstones
in 10% to 20% of patients. They are also expensive.
The GH receptor antagonist, pegvisomant (Somavert®)
Pegvisomant has a different mechanism of action. It acts
in the periphery, blocking the effects of GH on its target
organs by binding to GH receptors and preventing their
dimerization; this blocks GH signal transduction and
inhibits GH activity, including IGF-I production [94]. As
pegvisomant inhibits the action of GH but not its secre-
tion, GH concentrations cannot be used to evaluate treat-
ment efficacy. IGF-I is used as a surrogate marker, together
with clinical parameters. Pegvisomant is administered
subcutaneously at a daily dose of 10, 15 or 20 mg (some-
times more), the dose being adapted to the hormone
response (IGF-I normalization). Pegvisomant is highly
effective, as IGF-I levels normalize in more than 90% of
patients [95,96]. For the moment this treatment is
reserved for patients in whom somatostatin analogs fail. A
small increase in tumor volume is observed in a few
patients (possibly related to the natural history of the ade-
noma, or to growth stimulation), and this may justify
combination with an somatostatin to reduce tumor vol-
ume [97]. Tumor volume must therefore be monitored
(by MRI) during this treatment. Available clinical data on
pegvisomant concern a relatively small number of
patients and relatively short treatment periods. The
adverse effects are limited to rare cases of increased
transaminases that generally normalize either after inter-
ruption of the treatment or spontaneously. Exceptional
cases of true hepatitis were reported [98].
Current therapeutic strategy
The advantages, disadvantages and costs of treatment
must be taken into account.
A therapeutic strategy is proposed by the Authors on Fig-
ure 11. Currently, if surgical treatment fails to cure
acromegaly, medical treatment with somatostatin analogs
is recommended rather than radiotherapy. If somatostatin
analog therapy fails, it may be interesting to propose a
reoperation in case of important tumor remnant, before
another trial of somatostatin analog. Otherwise, one can
propose pegvisomant before resorting to radiotherapy.
The cost of these medical treatments, which may be
required indefinitely, must be weighed up against the
risks of radiotherapy. In any event, medical treatment will
be necessary while waiting for the effects of radiotherapy
to appear.
If surgery and radiotherapy are contraindicated, first-line
somatostatin therapy may be proposed.
All these treatments must be re-assessed on a yearly basis.
Prognosis and outcome
Acromegaly is associated with increased mortality [1].
According to series published in the 1980–1990s, about
60% of patients die from cardiovascular disease, 25%
from respiratory complications, and 15% from cancer. If
left untreated, patients with acromegaly would die about
10 years earlier than healthy subjects. Several studies have
shown that cerebrovascular disorders are a frequent cause
of death, especially among women, but they involved
patients treated in various ways and many years ago
(craniotomy, radiotherapy), and a deleterious effect of
these treatments (especially radiotherapy) cannot be
ruled out [99,100]. The standardized mortality index (the
ratio of observed mortality in the acromegalic population
to expected mortality in the general population) ranges
from 1.2 to 3.3. The post-treatment GH concentration is
probably the best predictor of survival, for all causes of
death, independently of the types of complication. Thus,
life expectancy outcomes can be stratified according to the
post-treatment GH concentration: if GH secretion is con-
trolled (<2 μg/l, or <5 mIU/l, or IGF-I normalization), life
expectancy merges with that of the matched general pop-
ulation [99,101]. High GH/IGF-I concentrations, arterial
hypertension, and cardiomyopathy are factors in a poor
prognosis, while the duration of symptoms and other fac-
tors (diabetes, lipid disorders and cancer) are less impor-
tant [30]. Quality of life is also altered in acromegaly, and
is partially improved by effective treatment [102]. Finally,
it must be stressed that, with the current therapeutic strat-
egy, the vast majority of acromegalic patients have very
good control of GH/IGF-I secretion and no problems
relating to tumor growth. Adverse effects are infrequentPage 13 of 17
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different from the situation only 20 years ago, before the
somatostatin analogs era. In addition, the use of more
stringent criteria to define cure, together with aggressive
treatment of comorbidity, has significantly improved the
outlook for patients with acromegaly [103]. However,
even if patients are cured or well-controlled, sequelae
(joint pain, deformities and altered quality of life) often
remain.
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